{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T08:25:34Z","timestamp":1788683134442,"version":"build-2803163510"},"reference-count":81,"publisher":"American Academy of Pediatrics (AAP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,7,1]]},"abstract":"<jats:title>This Clinical Report was retired January 2014.<\/jats:title>\n               <jats:p>National varicella immunization coverage using the current 1-dose immunization strategy has increased among vaccine-eligible children 19 through 35 months of age from 27% in 1997 to 88% by 2005. These high immunization rates have resulted in a 71% to 84% decrease in the reported number of varicella cases, an 88% decrease in varicella-related hospitalizations, a 59% decrease in varicella-related ambulatory care visits, and a 92% decrease in varicella-related deaths in 1- to 4-year-old children when compared with data from the prevaccine era. Despite this significant decrease, the number of reported cases of varicella has remained relatively constant during the past 5 to 6 years. Since vaccine effectiveness for prevention of disease of any severity has been 80% to 85%, a large number of cases of varicella continue to occur among people who already have received the vaccine (breakthrough varicella), and outbreaks of varicella have been reported among highly immunized populations of schoolchildren. The peak age-specific incidence has shifted from 3- to 6-year-old children in the prevaccine era to 9- to 11-year-old children in the postvaccine era for cases in both immunized and unimmunized children during these outbreaks. Outbreaks of varicella are likely to continue with the current 1-dose immunization strategy.<\/jats:p>\n               <jats:p>After administration of 2 doses of varicella vaccine in children, the immune response is markedly enhanced, with &amp;gt;99% of children achieving an antibody concentration (determined by glycoprotein enzyme-linked immunosorbent assay) of \u22655 U\/mL (an approximate correlate of protection) and a marked increase in geometric mean antibody titers after the second vaccine dose. The estimated vaccine efficacy over a 10-year observation period of 2 doses for prevention of any varicella disease is 98% (compared with 94% for 1 dose), with 100% efficacy for prevention of severe disease. Recipients of 2 doses of varicella vaccine are 3.3-fold less likely to have breakthrough varicella, compared with those who are given 1 dose, during the first 10 years after immunization.<\/jats:p>\n               <jats:p>To achieve greater levels of immunity with fewer serosusceptible people, greater protection against breakthrough varicella disease, and reduction in the number of outbreaks that occur nationwide among school-aged populations, a 2-dose varicella immunization strategy is now recommended for children \u226512 months of age.<\/jats:p>","DOI":"10.1542\/peds.2007-1089","type":"journal-article","created":{"date-parts":[[2007,7,2]],"date-time":"2007-07-02T16:35:25Z","timestamp":1183394125000},"page":"221-231","source":"Crossref","is-referenced-by-count":91,"title":["Prevention of Varicella: Recommendations for Use of Varicella Vaccines in Children, Including a Recommendation for a Routine 2-Dose Varicella Immunization Schedule"],"prefix":"10.1542","volume":"120","author":[{"name":"Committee on Infectious Diseases","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2007,7,1]]},"reference":[{"key":"2023092514111020200_R1","doi-asserted-by":"crossref","unstructured":"Galil K, Brown C, Lin F, Seward J. Hospitalizations for varicella in the United States, 1988 to 1999. Pediatr Infect Dis J.\u20082002;21:931\u2013935","DOI":"10.1097\/00006454-200210000-00009"},{"key":"2023092514111020200_R2","doi-asserted-by":"crossref","unstructured":"Meyer PA, Seward JF, Jumaan AO, Wharton M. Varicella mortality: trends before vaccine licensure in the United States, 1970\u20131994. J Infect Dis.\u20082000;182:383\u2013390","DOI":"10.1086\/315714"},{"key":"2023092514111020200_R3","doi-asserted-by":"crossref","unstructured":"Ratner AJ. Varicella-related hospitalizations in the vaccine era. Pediatr Infect Dis J.\u20082002;21:927\u2013931","DOI":"10.1097\/00006454-200210000-00008"},{"key":"2023092514111020200_R4","doi-asserted-by":"crossref","unstructured":"Davis MM, Patel MS, Gebremariam A. Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics.\u20082004;114:786\u2013792","DOI":"10.1542\/peds.2004-0012"},{"key":"2023092514111020200_R5","doi-asserted-by":"crossref","unstructured":"Zhou F, Harpaz R, Jumaan AO, Winston CA, Shefer A. Impact of varicella vaccination on health care utilization. JAMA.\u20082005;294:797\u2013802","DOI":"10.1001\/jama.294.7.797"},{"key":"2023092514111020200_R6","unstructured":"American Academy of Pediatrics, Committee on Infectious Diseases. Recommendations for the use of live attenuated varicella vaccine [published correction appears in Pediatrics. 1995;96:150\u2013151]. Pediatrics.\u20081995;95:791\u2013796"},{"key":"2023092514111020200_R7","unstructured":"Centers for Disease Control and Prevention. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep.\u20081996;45(RR-11):1\u201336"},{"key":"2023092514111020200_R8","unstructured":"Centers for Disease Control and Prevention. Prevention of varicella: update recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep.\u20081999;48(RR-6):1\u20135"},{"key":"2023092514111020200_R9","unstructured":"Centers for Disease Control and Prevention. ACIP provisional recommendations for prevention of varicella. 2006. Available at: www.cdc.gov\/nip\/vaccine\/varicella\/varicella_acip_recs_prov_june_2006.pdf. Accessed February 9, 2007"},{"key":"2023092514111020200_R10","unstructured":"Centers for Disease Control and Prevention. Varicella outbreak among vaccinated children: Nebraska, 2004. MMWR Morb Mortal Wkly Rep.\u20082006;55:749\u2013752"},{"key":"2023092514111020200_R11","unstructured":"Centers for Disease Control and Prevention. National, state, and urban area vaccination coverage among children aged 19\u201335 months: United States, 2005. MMWR Morb Mortal Wkly Rep.\u20082006;55:988\u2013993"},{"key":"2023092514111020200_R12","doi-asserted-by":"crossref","unstructured":"Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med.\u20082005;352:450\u2013458","DOI":"10.1056\/NEJMoa042271"},{"key":"2023092514111020200_R13","doi-asserted-by":"crossref","unstructured":"Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995\u20132000. JAMA.\u20082002;287:606\u2013611","DOI":"10.1001\/jama.287.5.606"},{"key":"2023092514111020200_R14","doi-asserted-by":"crossref","unstructured":"Seward JF, Zhang JX, Maupin TJ, Mascola L, Jumaan AO. Contagiousness of varicella in vaccinated cases: a household contact study. JAMA.\u20082004;292:704\u2013708","DOI":"10.1001\/jama.292.6.704"},{"key":"2023092514111020200_R15","doi-asserted-by":"crossref","unstructured":"Vazquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med.\u20082001;344:955\u2013960","DOI":"10.1056\/NEJM200103293441302"},{"key":"2023092514111020200_R16","doi-asserted-by":"crossref","unstructured":"Lopez AS, Guris D, Zimmerman L, et al. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose?Pediatrics.\u20082006;117(6). Available at: www.pediatrics.org\/cgi\/content\/full\/117\/6\/e1070","DOI":"10.1542\/peds.2005-2085"},{"key":"2023092514111020200_R17","doi-asserted-by":"crossref","unstructured":"Lee BR, Feaver SL, Miller CA, Hedberg CW, Ehresmann KR. An elementary school outbreak of varicella attributed to vaccine failure: policy implications. J Infect Dis.\u20082004;190:477\u2013483","DOI":"10.1086\/422041"},{"key":"2023092514111020200_R18","unstructured":"Centers for Disease Control and Prevention. Outbreak of varicella among vaccinated children: Michigan, 2003. MMWR Morb Mortal Wkly Rep.\u20082004;53:389\u2013392"},{"key":"2023092514111020200_R19","doi-asserted-by":"crossref","unstructured":"Ross AH, Lencher E, Reitman G. Modification of chickenpox in family contacts by administration of gamma globulin. N Engl J Med.\u20081962;267:369\u2013376","DOI":"10.1056\/NEJM196208232670801"},{"key":"2023092514111020200_R20","doi-asserted-by":"crossref","unstructured":"Kjersem H, Jepsen S. Varicella among immigrants from the tropics, a health problem. Scand J Soc Med.\u20081990;18:171\u2013174","DOI":"10.1177\/140349489001800303"},{"key":"2023092514111020200_R21","doi-asserted-by":"crossref","unstructured":"Wharton M. The epidemiology of varicella-zoster virus infections. Infect Dis Clin North Am.\u20081996;10:571\u2013581","DOI":"10.1016\/S0891-5520(05)70313-5"},{"key":"2023092514111020200_R22","doi-asserted-by":"crossref","unstructured":"Yawn BP, Yawn RA, Lydick E. Community impact of childhood varicella infections. J Pediatr.\u20081997;130:759\u2013765","DOI":"10.1016\/S0022-3476(97)80019-4"},{"key":"2023092514111020200_R23","unstructured":"Finger R, Hughes JP, Meade BJ, Pelletier AR, Palmer CT. Age-specific incidence of chickenpox. Public Health Rep.\u20081994;109:750\u2013755"},{"key":"2023092514111020200_R24","doi-asserted-by":"crossref","unstructured":"Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol.\u20082003;70(suppl 1):S111\u2013S118","DOI":"10.1002\/jmv.10364"},{"key":"2023092514111020200_R25","doi-asserted-by":"crossref","unstructured":"Alter SJ, Hammond JA, McVey CJ, Myers MG. Susceptibility to varicella-zoster virus among adults at high risk for exposure. Infect Control.\u20081986;7:448\u2013451","DOI":"10.1017\/S0195941700064936"},{"key":"2023092514111020200_R26","doi-asserted-by":"crossref","unstructured":"Ferson MJ, Bell SM, Robertson PW. Determination and importance of varicella immune status of nursing staff in a children's hospital. J Hosp Infect.\u20081990;15:347\u2013351","DOI":"10.1016\/0195-6701(90)90091-2"},{"key":"2023092514111020200_R27","doi-asserted-by":"crossref","unstructured":"Struewing JP, Hyams KC, Tueller JE, Gray GC. The risk of measles, mumps, and varicella among young adults: a serosurvey of US Navy and Marine Corps recruits. Am J Public Health.\u20081993;83:1717\u20131720","DOI":"10.2105\/AJPH.83.12.1717"},{"key":"2023092514111020200_R28","doi-asserted-by":"crossref","unstructured":"McKinney WP, Horowitz MM, Battiola RJ. Susceptibility of hospital-based health care personnel to varicella-zoster virus infections. Am J Infect Control.\u20081989;17:26\u201330","DOI":"10.1016\/S0196-6553(89)80009-4"},{"key":"2023092514111020200_R29","unstructured":"Perella D, Fiks A, Spain CV, et al. Validity of reported varicella history as a marker for varicella-zoster virus immunity. Presented at: the Pediatric Academic Societies\/Society for Pediatric Research annual meeting; May 14\u201317, 2005; Washington, DC. Abstract 692:57"},{"key":"2023092514111020200_R30","doi-asserted-by":"crossref","unstructured":"Gershon AA, Steinberg SP, Gelb L. Clinical reinfection with varicella-zoster virus. J Infect Dis.\u20081984;149:137\u2013142","DOI":"10.1093\/infdis\/149.2.137"},{"key":"2023092514111020200_R31","doi-asserted-by":"crossref","unstructured":"Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med.\u20081965;58:9\u201320","DOI":"10.1177\/003591576505800106"},{"key":"2023092514111020200_R32","doi-asserted-by":"crossref","unstructured":"Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect.\u20082001;127:305\u2013314","DOI":"10.1017\/S0950268801005921"},{"key":"2023092514111020200_R33","doi-asserted-by":"crossref","unstructured":"Kimberlin DW, Whitley RJ. Use of the varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med.\u20082007;356:1338\u20131343","DOI":"10.1056\/NEJMct066061"},{"key":"2023092514111020200_R34","doi-asserted-by":"crossref","unstructured":"Berger R, Florent G, Just M. Decrease of the lymphoproliferative response to varicella-zoster virus antigen in the aged. Infect Immun.\u20081981;32:24\u201327","DOI":"10.1128\/iai.32.1.24-27.1981"},{"key":"2023092514111020200_R35","doi-asserted-by":"crossref","unstructured":"Burke BL, Steele RW, Beard OW, Wood JS, Cain TD, Marmer DJ. Immune responses to varicella-zoster in the aged. Arch Intern Med.\u20081982;142:291\u2013293","DOI":"10.1001\/archinte.1982.00340150091016"},{"key":"2023092514111020200_R36","doi-asserted-by":"crossref","unstructured":"Levin MJ, Smith JG, Kaufhold RM, et al. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine. J Infect Dis.\u20082003;188:1336\u20131344","DOI":"10.1086\/379048"},{"key":"2023092514111020200_R37","doi-asserted-by":"crossref","unstructured":"Guess HA, Broughton DD, Melton LJ III, Kurland LT. Epidemiology of herpes zoster in children and adolescents: a population-based study. Pediatrics.\u20081985;76:512\u2013517","DOI":"10.1542\/peds.76.4.512"},{"key":"2023092514111020200_R38","doi-asserted-by":"crossref","unstructured":"Locksley RM, Flournoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis.\u20081985;152:1172\u20131181","DOI":"10.1093\/infdis\/152.6.1172"},{"key":"2023092514111020200_R39","doi-asserted-by":"crossref","unstructured":"Hardy I, Gershon AA, Steinberg SP, LaRussa P; Varicella Vaccine Collaborative Study Group. The incidence of zoster after immunization with live attenuated varicella vaccine: a study in children with leukemia. N Engl J Med.\u20081991;325:1545\u20131550","DOI":"10.1056\/NEJM199111283252204"},{"key":"2023092514111020200_R40","doi-asserted-by":"crossref","unstructured":"Meyers JD. Congenital varicella in term infants: risk reconsidered. J Infect Dis.\u20081974;129:215\u2013217","DOI":"10.1093\/infdis\/129.2.215"},{"key":"2023092514111020200_R41","doi-asserted-by":"crossref","unstructured":"Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet.\u20081974;2(7892):1288\u20131290","DOI":"10.1016\/S0140-6736(74)90144-5"},{"key":"2023092514111020200_R42","unstructured":"Varivax [package insert]. Whitehouse Station, NJ: Merck & Co Inc; 2005. Available at: www.fda.gov\/cber\/label\/varmer040505LBr.pdf. Accessed February 9, 2007"},{"key":"2023092514111020200_R43","unstructured":"ProQuad [package insert]. Whitehouse Station, NJ: Merck & Co Inc; 2005. Available at: www.fda.gov\/CbER\/label\/mmrvmer090605LB.pdf. Accessed February 9, 2007"},{"key":"2023092514111020200_R44","unstructured":"Zostavax [package insert]. Whitehouse Station, NJ: Merck & Co Inc; 2006. Available at: www.fda.gov\/CbER\/label\/zosmer052506LB.pdf. Accessed February 9, 2007"},{"key":"2023092514111020200_R45","doi-asserted-by":"crossref","unstructured":"Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med.\u20082005;352:2271\u20132284","DOI":"10.1056\/NEJMoa051016"},{"key":"2023092514111020200_R46","doi-asserted-by":"crossref","unstructured":"Wreghitt TG, Tedder RS, Nagington J, Ferns RB. Antibody assays for varicella-zoster virus: comparison of competitive enzyme-linked immunosorbent assay (ELISA), competitive radioimmunoassay (RIA), complement fixation, and indirect immunofluorescence assays. J Med Virol.\u20081984;13:361\u2013370","DOI":"10.1002\/jmv.1890130407"},{"key":"2023092514111020200_R47","doi-asserted-by":"crossref","unstructured":"Steinberg SP, Gershon AA. Measurement of antibodies to varicella-zoster virus by using a latex agglutination test. J Clin Microbiol.\u20081991;29:1527\u20131529","DOI":"10.1128\/jcm.29.7.1527-1529.1991"},{"key":"2023092514111020200_R48","doi-asserted-by":"crossref","unstructured":"Provost PJ, Krah DL, Kuter BJ, et al. Antibody assays suitable for assessing immune responses to live varicella vaccine. Vaccine.\u20081991;9:111\u2013116","DOI":"10.1016\/0264-410X(91)90266-9"},{"key":"2023092514111020200_R49","doi-asserted-by":"crossref","unstructured":"Behrman A, Schmid DS, Crivaro A, Watson B. A cluster of primary varicella cases among healthcare workers with false-positive varicella zoster virus titers. Infect Control Hosp Epidemiol.\u20082003;24:202\u2013206","DOI":"10.1086\/502187"},{"key":"2023092514111020200_R50","doi-asserted-by":"crossref","unstructured":"Chan IS, Li S, Matthews H, et al. Use of statistical models for evaluating antibody response as a correlate of protection against varicella. Stat Med.\u20082002;21:3411\u20133430","DOI":"10.1002\/sim.1268"},{"key":"2023092514111020200_R51","doi-asserted-by":"crossref","unstructured":"Li S, Chan IS, Matthews H, et al. Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis J.\u20082002;21:337\u2013342","DOI":"10.1097\/00006454-200204000-00014"},{"key":"2023092514111020200_R52","unstructured":"White CJ, Kuter BJ, Hildebrand CS, et al. Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics.\u20081991;87:604\u2013610"},{"key":"2023092514111020200_R53","doi-asserted-by":"crossref","unstructured":"Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J.\u20082004;23:132\u2013137","DOI":"10.1097\/01.inf.0000109287.97518.67"},{"key":"2023092514111020200_R54","doi-asserted-by":"crossref","unstructured":"Watson B, Gupta R, Randall T, Starr S. Persistence of cell-mediated and humoral immune responses in healthy children immunized with live attenuated varicella vaccine. J Infect Dis.\u20081994;169:197\u2013199","DOI":"10.1093\/infdis\/169.1.197"},{"key":"2023092514111020200_R55","doi-asserted-by":"crossref","unstructured":"Shinefield H, Black S, Digilio L, et al. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J.\u20082005;24:665\u2013669","DOI":"10.1097\/01.inf.0000172902.25009.a1"},{"key":"2023092514111020200_R56","doi-asserted-by":"crossref","unstructured":"Shinefield H, Black S, Thear M, et al. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate\/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. Pediatr Infect Dis J.\u20082006;25:287\u2013292","DOI":"10.1097\/01.inf.0000207857.10947.1f"},{"key":"2023092514111020200_R57","unstructured":"Michalik DE, LaRussa PS, Steinberg SP, Wright P, Edwards K, Gershon AA. Primary immune failure after one dose of varicella vaccine are likely a cause of breakthrough infections in healthy vaccinated children. Presented at: 44th Annual Meeting of the Infectious Diseases Society of America; October 12\u201315, 2006; Toronto, Ontario, Canada. Abstract 146"},{"key":"2023092514111020200_R58","doi-asserted-by":"crossref","unstructured":"Watson B, Rothstein E, Bernstein H, et al. Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. J Infect Dis.\u20081995;172:217\u2013219","DOI":"10.1093\/infdis\/172.1.217"},{"key":"2023092514111020200_R59","doi-asserted-by":"crossref","unstructured":"Kuter BJ, Ngai A, Patterson CM, et al. Safety, tolerability, and immunogenicity of two regimens of Oka\/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Vaccine.\u20081995;13:967\u2013972","DOI":"10.1016\/0264-410X(95)00046-4"},{"key":"2023092514111020200_R60","doi-asserted-by":"crossref","unstructured":"Gershon AA, Steinberg SP, LaRussa P, Ferrara A, Hammerschlag M, Gelb L. Immunization of healthy adults with live attenuated varicella vaccine. J Infect Dis.\u20081988;158:132\u2013137","DOI":"10.1093\/infdis\/158.1.132"},{"key":"2023092514111020200_R61","doi-asserted-by":"crossref","unstructured":"Saiman L, LaRussa P, Steinberg SP, et al. Persistence of immunity to varicella-zoster virus after vaccination of healthcare workers. Infect Control Hosp Epidemiol.\u20082001;22:279\u2013283","DOI":"10.1086\/501900"},{"key":"2023092514111020200_R62","doi-asserted-by":"crossref","unstructured":"Ampofo K, Saiman L, LaRussa P, Steinberg S, Annunziato P, Gershon A. Persistance of immunity to live attenuated varicella vaccine in healthy adults. Clin Infect Dis.\u20082002;34:774\u2013779","DOI":"10.1086\/338959"},{"key":"2023092514111020200_R63","doi-asserted-by":"crossref","unstructured":"Watson B, Boardman C, Laufer D, et al. Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clin Infect Dis.\u20081995;20:316\u2013319","DOI":"10.1093\/clinids\/20.2.316"},{"key":"2023092514111020200_R64","doi-asserted-by":"crossref","unstructured":"Weibel RE, Neff BJ, Kuter BJ, et al. Live attenuated varicella virus vaccine: efficacy trial in healthy children. N Engl J Med.\u20081984;310:1409\u20131415","DOI":"10.1056\/NEJM198405313102201"},{"key":"2023092514111020200_R65","unstructured":"Arbeter AM, Starr SE, Plotkin SA. Varicella vaccine studies in healthy children and adults. Pediatrics.\u20081986;78(4 pt 2):748\u2013756"},{"key":"2023092514111020200_R66","doi-asserted-by":"crossref","unstructured":"Kuter BJ, Weibel RE, Guess HA, et al. Oka\/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine.\u20081991;9:643\u2013647","DOI":"10.1016\/0264-410X(91)90189-D"},{"key":"2023092514111020200_R67","doi-asserted-by":"crossref","unstructured":"Krause PR, Klinman DM. Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. J Pediatr.\u20081995;127:518\u2013525","DOI":"10.1016\/S0022-3476(95)70106-0"},{"key":"2023092514111020200_R68","doi-asserted-by":"crossref","unstructured":"Buchholz U, Moolenaar R, Peterson C, Mascola L. Varicella outbreaks after vaccine licensure: should they make you chicken?Pediatrics.\u20081999;104:561\u2013563","DOI":"10.1542\/peds.104.3.561"},{"key":"2023092514111020200_R69","doi-asserted-by":"crossref","unstructured":"Dworkin MS, Jennings CE, Roth-Thomas J, Lang JE, Stukenberg C, Lumpkin JR. An outbreak of varicella among children attending preschool and elementary school in Illinois. Clin Infect Dis.\u20082002;35:102\u2013104","DOI":"10.1086\/340868"},{"key":"2023092514111020200_R70","doi-asserted-by":"crossref","unstructured":"Galil K, Fair E, Mountcastle N, Britz P, Seward J. Younger age at vaccination may increase risk of varicella vaccine failure. J Infect Dis.\u20082002;186:102\u2013105","DOI":"10.1086\/341089"},{"key":"2023092514111020200_R71","doi-asserted-by":"crossref","unstructured":"Izurieta HS, Strebel PM, Blake PA. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA.\u20081997;278:1495\u20131499","DOI":"10.1001\/jama.278.18.1495"},{"key":"2023092514111020200_R72","doi-asserted-by":"crossref","unstructured":"Marin M, Nguyen HQ, Keen J, et al. Importance of catch-up vaccination: experience from a varicella outbreak, Maine, 2002\u20132003. Pediatrics.\u20082005;115:900\u2013905","DOI":"10.1542\/peds.2004-1162"},{"key":"2023092514111020200_R73","doi-asserted-by":"crossref","unstructured":"Tugwell BD, Lee LE, Gillette H, Lorber EM, Hedberg K, Cieslak PR. Chickenpox outbreak in a highly vaccinated school population. Pediatrics.\u20082004;113:455\u2013459","DOI":"10.1542\/peds.113.3.455"},{"key":"2023092514111020200_R74","doi-asserted-by":"crossref","unstructured":"Vazquez M, LaRussa PS, Gershon AA, et al. Effectiveness over time of varicella vaccine. JAMA.\u20082004;291:851\u2013855","DOI":"10.1001\/jama.291.7.851"},{"key":"2023092514111020200_R75","doi-asserted-by":"crossref","unstructured":"Sharrar RG, LaRussa P, Galea SA, et al. The postmarketing safety profile of varicella vaccine. Vaccine.\u20082000;19:916\u2013923","DOI":"10.1016\/S0264-410X(00)00297-8"},{"key":"2023092514111020200_R76","doi-asserted-by":"crossref","unstructured":"Salzman MB, Sharrar RG, Steinberg S, LaRussa P. Transmission of varicella-vaccine virus from a healthy 12-month-old child to his pregnant mother. J Pediatr.\u20081997;131:151\u2013154","DOI":"10.1016\/S0022-3476(97)70140-9"},{"key":"2023092514111020200_R77","doi-asserted-by":"crossref","unstructured":"Grossberg R, Harpaz R, Rubtcova E, Loparev V, Seward JF, Schmid DS. Secondary transmission of varicella vaccine virus in a chronic care facility for children. J Pediatr.\u20082006;148:842\u2013844","DOI":"10.1016\/j.jpeds.2006.01.038"},{"key":"2023092514111020200_R78","doi-asserted-by":"crossref","unstructured":"American Academy of Pediatrics, Committee on Infectious Diseases. Combination vaccines for childhood immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP). Pediatrics.\u20081999;103:1064\u20131077","DOI":"10.1542\/peds.103.5.1064"},{"key":"2023092514111020200_R79","unstructured":"American Academy of Pediatrics. Varicella-zoster infections. In: Pickering LK, Baker CJ, Long SS, McMillan JA, eds. Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006:711\u2013725"},{"key":"2023092514111020200_R80","unstructured":"Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep.\u20082006;55(RR-15):1\u201348"},{"key":"2023092514111020200_R81","unstructured":"American Academy of Pediatrics. Immunizations in special clinical circumstances. In: Pickering LK, Baker CJ, Long SS, McMillan JA, eds. Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006:67\u2013103"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/120\/1\/221\/1531381\/zpe00707000221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/120\/1\/221\/1531381\/zpe00707000221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T14:11:40Z","timestamp":1695651100000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/120\/1\/221\/70513\/Prevention-of-Varicella-Recommendations-for-Use-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,1]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2007,7,1]]},"published-print":{"date-parts":[[2007,7,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2007-1089","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,1]]}}}